Guilford looks to place $59 million:
This article was originally published in Clinica
Executive Summary
Guilford Pharmaceuticals has announced a definitive agreement for private placement of three million shares with institutions, raising proceeds of $59 million before expenses and commissions. Guilford develops products for the diagnosis and treatment of neurological disorders and biopolymer-based therapeutics for cancer and other conditions.